Affiliation: Tokyo Medical and Dental University
- Pycnogenol, a procyanidin-rich extract from French maritime pine, inhibits intracellular replication of HIV-1 as well as its binding to host cellsWu Yu Feng
Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, Tokyo 113 5819, Japan
Jpn J Infect Dis 61:279-85. 2008..Inhibition of HIV-1 replication associated with induced expression of Mn-SOD in cells treated with PYC suggests the potential of this natural antioxidant inducer as a new anti-HIV-1 agent...
- Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium AitonYu Zhong
Department of Molecular Virology, Bio-Response, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Tokyo 113-8519, Japan
Antiviral Res 66:119-28. 2005..The inhibitory activity of the extract was also not reduced after pronase digestion. The active factor in the extract is likely to be a novel compound(s) having a polyanionic substructure and a molecular weight of 10,000-50,000...
- Utilization of host SR protein kinases and RNA-splicing machinery during viral replicationTakeshi Fukuhara
Laboratory of Gene Expression, School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
Proc Natl Acad Sci U S A 103:11329-33. 2006..Thus, we show that SRPK, a well known kinase in the cellular RNA-processing machinery, is used by at least some viruses for propagation and hence suggest that SRPIN340 or its derivatives may be useful for curbing viral diseases...
- HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirusNorio Yamamoto
Department of Molecular Virology, Bio Response, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
Biochem Biophys Res Commun 318:719-25. 2004..Our results suggest that nelfinavir should be examined clinically for the treatment of SARS and has potential as a good lead compound for designing anti-SARS drugs...
- The development of vaccines against SARS corona virus in mice and SCID-PBL/hu miceMasaji Okada
Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591 8555, Japan
Vaccine 23:2269-72. 2005..As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines...
- Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse modelsMasaji Okada
Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan
Adv Exp Med Biol 581:561-6. 2006..These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines...